Nasdaq:US$ () | HKEX:HK$ () | AIM:£0.00 (0)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


2023 Full Year Financial Results 2024-02-28 - 2024-02-29
Sinolink Securities 2024 Spring Strategy Conference, Shanghai 2024-01-11
Citi’s 2024 China Healthcare Corporate Day, Hong Kong 2024-01-18